Search
Bismuth subnitrate
go.drugbank.com/drugs/DB13209ApprovedWithdrawnThe use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA.
Dimethicone 410
go.drugbank.com/drugs/DB14005Approved[L1769] It is currently recognized by the FDA as a skin protectant OTC ingredient for human use in a concentration of 1-30%. … Dimethicone is a silicone-based polymer used as a moisturizer in different skin OTC products.[A32462] It is formed by repeated polymeric units of -(CH3)2SiO- with a terminal trimethyl siloxy unit.
Desflurane
go.drugbank.com/drugs/DB01189ApprovedInvestigationalIt was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285]
Palovarotene
go.drugbank.com/drugs/DB05467ApprovedFibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. … [A244920] Palovarotene was approved for use in Canada in January 2022 for the management of heterotopic ossification (HO) in patients with FOP, representing the first global approval for any FOP therapy
Pemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigational[A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast … [A198963] The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials.
Tyloxapol
go.drugbank.com/drugs/DB06439ApprovedInvestigationalTyloxapol is a non-ionic detergent often used as a surfactant.
Categories: Compounds used in a research, industrial, or household settingSatralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigationalan IgG2 framework. … [eculizumab] in June 2019 and [inebilizumab] in June 2020).
Products: ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML, ENSPRYNG 120 mg/1ml solution for injection in pre-filled syringeApadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigational[A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP. … metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible for cleaving large von Willebrand factor multimers and preventing the formation of microthrombi - this deficiency in
Sarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalThe acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well [L4814]. … s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients
Binimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigational[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients … with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.